AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund. Schroer added that AbbVie’s purchase of Pharmacyclics will also fill gaps in the company’s pipeline. He is also bullish on Vertex, saying the company’s new cystic fibrosis combination therapy will substantially expand its treatable base, adding the company has a good chance of being acquired in this heightened M&A environment. Finally, Schroer is bullish on Biogen shares due to its pipeline and potential earnings growth.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
